Vor Bio to Participate in Upcoming Investor Conferences
Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) has announced its participation in several upcoming investor conferences. Key events include:
- Credit Suisse 31st Annual Healthcare Conference: Virtual presentation on November 8, 2022.
- Stifel 2022 Healthcare Conference: Fireside chat on November 16, 2022, at 10:20 am EST in New York, NY.
- Jefferies London Healthcare Conference: Fireside chat on November 17, 2022, at 3:15 pm GMT in London, UK.
Webcasts of these events will be available on Vor Bio's investor section.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -2.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Credit Suisse 31st Annual Healthcare Conference
A virtual presentation will be made live starting on Tuesday, November 8, 2022
Stifel 2022 Healthcare Conference
Fireside chat: Wednesday, November 16, 2022 at 10:20 am EST
Location: Lotte New York Palace Hotel, New York, NY
Jefferies London Healthcare Conference
Fireside chat: Thursday, November 17, 2022 at 3:15 pm GMT (10:15 am EST)
Location: The Waldorf Hilton, London, UK
A live webcast and archived replay of the fireside chats along with a replay of the pre-recorded presentation will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.